Literature DB >> 3888456

Type III procollagen peptide and PZ-peptidase serum levels in pre-cirrhotic liver diseases.

A Morelli, A Vedovelli, S Fiorucci, G P Angelini, C Fini, C A Palmerini, A Floridi.   

Abstract

To obtain a dynamic and non-invasive picture of hepatic fibrosis in pre-cirrhotic liver diseases we measured both the concentration of the N-terminal peptide of procollagen III, as a marker of collagen synthesis, and the activity of PZ-peptidase, an enzyme involved in collagen degradation, in the serum of alcoholic or chronic viral hepatitis patients. Peptide serum levels were similar in chronic persistent hepatitis and controls, but significantly higher in chronic active hepatitis. Chronic persistent hepatitis patients had PZ-peptidase levels higher than controls, but similar to chronic active hepatitis. The increase in collagen synthesis without a parallel increase in collagen degradation seen in chronic active hepatitis could be regarded as a sign of impending cirrhosis, whereas the unbalanced rise in PZ-peptidase observed in chronic persistent hepatitis is consistent with the non-progressive character of this disorder. In alcoholic hepatitis both peptide concentration and PZ-peptidase activity were elevated, thus suggesting that both collagen synthesis and degradation are activated. However, the greater increase in PZ-peptidase than in peptide serum levels seen in some patients seems to indicate a minor tendency to progressive fibrosis or a trend towards resolution. Unlike liver disease patients, normal peptide and PZ-peptidase levels were found in patients with pancreatic fibrosis. Since circulating inhibitors and activators of the PZ-peptidase activity can be excluded, as proved by this study, joint peptide and PZ-peptidase serum measurements would seem to offer a simple reliable non-invasive method for differentiating and monitoring progressive and non-progressive forms of hepatic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3888456     DOI: 10.1016/0009-8981(85)90217-7

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  3 in total

1.  Serum levels of type III collagen aminopropeptide in patients with systemic scleroderma.

Authors:  S Majewski; A Skiendzielewska; B Makieła; S Jablońska; M Błaszczyk
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

2.  An immunohistochemical and serum ELISA study of type I and III procollagen aminopropeptides in primary biliary cirrhosis.

Authors:  B H Davis; J A Madri
Journal:  Am J Pathol       Date:  1987-08       Impact factor: 4.307

3.  Serum laminin--its concentration increases with portal hypertension in cirrhotic liver disease.

Authors:  A M Gressner; W Tittor
Journal:  Klin Wochenschr       Date:  1986-12-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.